Advertisement

The Potential of Positron-Emission Tomography for Pharmacokinetic and Pharmacodynamic Studies of Neuroleptics

  • L. Farde
  • F.-A. Wiesel
  • L. Nilsson
  • G. Sedvall
Conference paper
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 7)

Abstract

The antipsychotic effect of neuroleptic drugs is well established (Delay and Deniker 1957; Klein and Davis 1962). The individual response to treatment with neuroleptic drugs is, however, highly variable. Some patients do not respond to treatment, and in some patients severe side effects are recorded. For such reasons there is a need for useful methods to examine the mechanism of antipsychotic drug action in patients and for measures to guide the determination of proper dosage. During the past 20 years techniques have been available for the measurement of drug concentrations in body fluids. Despite a large number of studies on the relationships between serum drug concentrations and antipsychotic effect, no consistent relationships have been generally confirmed (Dahl 1986).

Keywords

Antipsychotic Drug Receptor Occupancy Neuroleptic Drug Serum Drug Concentration Antipsychotic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini RJ, Davis JM (1980) What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 3: 115–122PubMedCrossRefGoogle Scholar
  2. Cambon H, Baron JC, Boulenger JP, Loch C, Zarifian E, Maziere B (1987) In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans. Br J Psychiatry 151: 824–830PubMedCrossRefGoogle Scholar
  3. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh) 20: 140–144CrossRefGoogle Scholar
  4. Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding, clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483PubMedCrossRefGoogle Scholar
  5. Dahl SG (1986) Plasma level monitoring of antipsychotic drugs’ clinical utility. Clin Pharmacokinet 11: 36–61PubMedCrossRefGoogle Scholar
  6. Deniker P (1978) Impact of neuroleptic chemotherapies on schizophrenic psychosis. Am J Psychiatry 135: 923–927PubMedGoogle Scholar
  7. Farde L, Wiesel F-A, Ehrin E, Hall H, Sedvall G (1986a) Quantitative PET-scan determination of dopamine-D2 receptor binding in schizophrenic patients treated with distinct classes of antipsychotic drugs. In: Shagass C, et al. (eds) World Congress of Biological Psychiatry, 8–13 September 1985. Elsevier, New York, pp 363–365 (Developments in psychiatry, vol 7 )Google Scholar
  8. Farde L, Hall H, Ehrin E, Sedvall G (1986b) Quantitative analysis of dopamine-D2 receptor binding in the living human brain by positron emission tomography. Science 231: 258–261PubMedCrossRefGoogle Scholar
  9. Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S, Sedvall G (1987) No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 44: 671PubMedGoogle Scholar
  10. Farde L, Wiesel F-A, Halldin H, Sedvall G (1988 a) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76Google Scholar
  11. Farde L, Pauli S, Hall H, Eriksson L, Halldin C, Hogberg T, Nilsson, Sjogren I (1988b) Stereoselective binding of 11C-raclopride in living human brain — a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berlin) 94: 471–478CrossRefGoogle Scholar
  12. Farde L, Wiesel F-A, Jansson P, Uppfeldt G, Wahlen A, Sedvall G (1988c) An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berlin) 94: 1–7CrossRefGoogle Scholar
  13. Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111–174Google Scholar
  14. Klein D, Davis J (1962) Diagnosis and drug treatment of psychiatric disorders. Williams and Williams, BaltimoreGoogle Scholar
  15. Marder SR, van Putten T, Mintz J, et al. (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029PubMedGoogle Scholar
  16. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, adrenergic and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522PubMedGoogle Scholar
  17. Sedvall G, Farde L, Persson A, Wiesel F-A (1986) Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 43: 995–1005PubMedGoogle Scholar
  18. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717–719PubMedCrossRefGoogle Scholar
  19. Smith M, Wolf AD, Brodie JD, Arnett CD, Barouche F, Shine C-Y, Fowler JS, Russell JAG, MacGregor RR, Wolkin A, Angrist B, Rotrosen J, Peselow E (1988) Serial [18F]N-Methylspiroperidol PET studies to measure changes in anti-psychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry 23: 653–663PubMedCrossRefGoogle Scholar
  20. Wagner HN, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, et al. (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221: 1264–1266PubMedCrossRefGoogle Scholar
  21. Wode-Helgodt B, Borg S, Fyro B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • L. Farde
    • 1
  • F.-A. Wiesel
    • 1
  • L. Nilsson
    • 2
  • G. Sedvall
    • 2
  1. 1.Department of Psychiatry and PsychologyKarolinska Institute and HospitalStockholmSweden
  2. 2.Astra Alab ABSödertäljeSweden

Personalised recommendations